MedTrace Logo

Investigation of Cisplatin-Related Kidney Toxicity

NCT00984035 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2018-09-11

No results posted yet for this study

Summary

The purpose of this study is to identify novel biomarkers of kidney injury in patients receiving cisplatin.

This study will also collect DNA for future analysis.

Conditions

Interventions

OTHER

urine samples (biomarkers)

Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.

OTHER

blood samples (biomarkers)

blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.

OTHER

blood sample (DNA)

Blood sample collected for DNA analysis at anytime while on-study.

Sponsors & Collaborators

Principal Investigators

  • Peter H O'Donnell, MD · University of Chicago

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-22
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984035 on ClinicalTrials.gov